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Abstract
Hepatic cysts are increasingly found as a mere coinci-
dence on abdominal imaging techniques, such as ul-
trasonography (USG), computed tomography (CT) and 
magnetic resonance imaging (MRI). These cysts often 
present a diagnostic challenge. Therefore, we per-
formed a review of the recent literature and developed 
an evidence-based diagnostic algorithm to guide clini-
cians in characterising these lesions. Simple cysts are 
the most common cystic liver disease, and diagnosis 
is based on typical USG characteristics. Serodiagnostic 
tests and microbubble contrast-enhanced ultrasound 
(CEUS) are invaluable in differentiating complicated 
cysts, echinococcosis and cystadenoma/cystadeno-
carcinoma when USG, CT and MRI show ambiguous 
findings. Therefore, serodiagnostic tests and CEUS re-
duce the need for invasive procedures. Polycystic liver 
disease (PLD) is arbitrarily defined as the presence of 
> 20 liver cysts and can present as two distinct genetic 
disorders: autosomal dominant polycystic kidney dis-
ease (ADPKD) and autosomal dominant polycystic liver 
disease (PCLD). Although genetic testing for ADPKD 
and PCLD is possible, it is rarely performed because it 
does not affect the therapeutic management of PLD. 
USG screening of the liver and both kidneys combined 
with extensive family history taking are the cornerstone 
of diagnostic decision making in PLD. In conclusion, an 
amalgamation of these recent advances results in a di-
agnostic algorithm that facilitates evidence-based clini-
cal decision making.
© 2013 Baishideng. All rights reserved.
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Core tip: We performed a review of the recent litera-
ture, and through combining current consensus and 
recent advances, we developed an evidence-based 
diagnostic algorithm to guide clinicians in characteris-
ing hepatic cystic lesions. Serodiagnostic tests and 
microbubble contrast-enhanced ultrasound (CEUS) are 
invaluable in differentiating complicated cysts, echino-
coccosis and cystadenoma/cystadenocarcinoma when 
ultrasonography (USG), computed tomography and 
magnetic resonance imaging show ambiguous findings. 
As a result, serodiagnostic tests and CEUS reduce the 
need for invasive procedures. USG screening of the 
liver and both kidneys combined with extensive family 
history taking remains the cornerstone of diagnostic 
decision making in polycystic liver disease.
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INTRODUCTION
Hepatic cystic lesions represent a comprehensive het-
erogeneous cluster with regard to pathogenesis, clinical 
presentation, diagnostic findings and therapeutic man-
agement (Table 1). Hepatic cystic lesions predominantly 
remain asymptomatic and are found as a mere coinci-
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dence on abdominal imaging techniques, such as ultra-
sonography (USG), computed tomography (CT) and 
magnetic resonance imaging (MRI)[1,2]. The use of  these 
techniques has greatly increased over the last years, and as 
a corollary, there has been an increase in incidental find-
ings of  asymptomatic hepatic cystic lesions[3]. In most 
cases, hepatic cystic lesions will follow a benign course[4]. 
However, it is essential to differentiate benign cysts from 
potentially harmful cysts, such as echinococcosis, cystad-
enoma and cystadenocarcinoma, which require specific 
treatment[5,6]. Currently, clinicians must also be aware of  
changes in the epidemiology of  certain hepatic cystic 
lesions. Echinococcosis has spread to previously non-
endemic Western European countries[7,8]. For this reason, 
the early and accurate diagnosis of  cysts is crucial. To fa-
cilitate the diagnostic process, we provide an overview of  
the wide spectrum of  mono- and polycystic liver diseases 
based on literature published over the last five years. 
LITERATURE SEARCH 
We searched the electronic database PubMed using the 
following search terms: “liver” and “cyst” and “diagno-
sis”. We limited our search to articles that were written 
in English, published between November 2007 and No-
vember 2012 and available in full text. A total of  992 ar-
ticles were identified. For the purpose of  this review, we 
included articles with a main focus on the evaluation of  
hepatic cystic lesions in humans. Screening the titles and 
abstracts identified 252 articles meeting these inclusion 
criteria (Figure 1). Additionally, we searched the reference 
lists from all eligible reviews for additional leads. 
SIMPLE CYSTS
Pathogenesis
Simple cysts arise congenitally from aberrant bile duct 
cells and contain a clear, bile-like fluid[9]. Because bile 
duct epithelium covers the simple cyst inner lining, it is 
hypothesised that simple cysts arise during embryogen-
esis when intrahepatic ductules fail to connect with extra-
hepatic ducts[4,10].
Clinical features
The prevalence of  simple cysts ranges from 2.5% to 18% 
and increases with age[11,12]. More than half  of  individuals 
older than 60 years are likely to have one or more simple 
cysts. Cysts are small in most patients but can grow to 
over 30 cm in selected cases. In a small fraction of  pa-
tients, symptoms, such as abdominal pain, early satiety, 
nausea and vomiting, arise as a result of  a mass effect[3]. 
Physical examination may reveal a palpable abdominal 
mass or hepatomegaly[1]. Complications such as haemor-
rhage, rupture and biliary obstruction are uncommon but 
are more likely in larger cysts[13]. Intracystic haemorrhage 
is a rare complication of  simple cysts and usually presents 
with severe abdominal pain[14], although asymptomatic 
presentations are also observed[15,16].
Laboratory findings
Laboratory findings are predominantly normal, but 
a minority of  patients have raised serum γ-glutamyl-
transferase (γGT)[17]. Several studies have shown that 
serum and cyst fluid levels of  carcinoembryonic antigen 
(CEA) and cancer antigen 19-9 (CA 19-9) may be el-
evated[18]. CA 19-9 is expressed in the simple cyst inner 
epithelial lining and leads to elevated cyst fluid and serum 
CA 19-9 levels[17]. CA 19-9 is not helpful in the differen-
tial diagnosis of  intracystic haemorrhage[19].
Diagnostic features
Most simple cysts are diagnosed incidentally on USG 
(Figure 2A), CT (Figure 2B) or MRI. The diagnosis of  
a simple cyst is based on the following USG criteria: 
anechoic (i.e., fluid filled cavity), no septations, sharp 
smooth borders, strong posterior wall echoes (indicating 
a well-defined fluid/tissue interface), spherical or oval 
shaped and a relative accentuation of  echoes beyond the 
cyst compared to echoes at a similar depth transmitted 
through normal adjacent hepatic tissue (Table 2)[20]. CT 
shows a sharply defined homogeneous hypodense lesion 
(Figure 2B)[21]. MRI T1-weighted sequence shows low 
signal intensity, whereas the T2-weighted sequence shows 
extremely high signal intensity, which does not enhance 
after contrast injection[22]. USG has a reported sensitivity 
and specificity of  approximately 90% for diagnosing a 
simple cyst[23], and recent advances in CT and MRI tech-
nology might result in even higher sensitivity rates[12,22,24]. 
However, because CT is accompanied with a radiation 
load and both CT and MRI come at a significantly higher 
cost, USG remains the most accurate, non-invasive and 
cost-effective imaging modality for diagnosing simple 
cysts.
In case of  an intracystic haemorrhage (i.e., complicated 
cyst), USG typically shows a hyperechogenic echo pat-
tern combined with internal echoes that mimic septations 
or solid portions (Figure 3)[25]. In contrast, CT visualises 
intracystic haemorrhage as a high-density area[26], whereas 
MRI depicts it as a high signal intensity on T1- and T2-
weighted sequences[27]. Neither CT nor MRI has addition-
al diagnostic value compared to USG in the diagnosis of  
cystic bleeding[15]. The recent development of  microbub-
ble contrast-enhanced ultrasound (CEUS) enables us to 
visualise vascular flow within septa or solid components 
of  cysts, which is absent in simple cysts with intracystic 
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Table 1  Differential diagnosis of cystic lesions in the liver
Monocytic disease
   Simple cyst
   Echinococcosis 
      Cystic echinococcosis
      Alveolar echinococcosis
   Cystadenoma 
   Cystadenocarcinoma
Polycystic disease
   Autosomal dominant polycystic kidney disease
   Autosomal dominant polycystic liver disease
haemorrhage[28]. Therefore, CEUS can accurately charac-
terise these cysts when USG, CT and MRI show ambigu-
ous findings[29-31].
Therapy
The management of  most simple cysts relies on a “wait-
and-see” policy, and no further treatment is required in 
these cases. If  there are symptoms, aspiration-sclerother-
apy is the preferred treatment[32,33]. Laparoscopic or open 
surgical fenestration techniques are similarly or even 
more effective in reducing symptoms[34,35] but have a sig-
nificantly higher morbidity and mortality rate[36]. 
ECHINOCOCCOSIS
Echinococcosis is a zoonosis caused by larval stages of  
taeniid cestodes (tapeworms) belonging to the Echinococcus 
species. Two of  the six known species cause solitary cys-
tic lesions in humans: (1) Echinococcus granulosus (E. granu-
losus), responsible for cystic echinococcosis (CE); and (2) 
Echinococcus multilocularis (E. multilocularis), responsible for 
alveolar echinococcosis (AE)[6]. 
Echinococcosis-related deaths are uncommon in 
developed countries. For example, there were 41 echino-
coccosis-associated deaths in the United States over an 
18-year study period[37]. However, echinococcosis is con-
sidered to be an emerging disease in Europe[38,39]. Thus, 
CE and AE are diseases with a considerable global dis-
ease impact, as indicated by a substantial loss in disability-
adjusted life years[38,40]. 
Cystic echinococcosis
Pathogenesis: Humans become infected by acting as 
intermediate hosts of  E. granulosus after ingestion of  Echi-
nococcus eggs, which are excreted by infected carnivores 
(dogs and other canids)[6]. Infection is typically observed 
in areas containing large numbers of  the intermediate 
hosts of  the parasite (sheep and goats) that are in close 
contact with the final host (herding dogs)[41-43].
Clinical features: Although CE has a worldwide geo-
graphic distribution, the highest prevalence of  CE is 
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PubMed query: "liver" and "cyst" 
and "diagnosis" n  = 6809
Articles excluded: n  = 5817
Exclusion criteria (articles may be excluded for one or more criteria): 
1: Not published in English: n  = 1991
2: Not published in last 5 years (november 2007 - november 2012): n  = 5547
3: Full text not available: n  = 2945
Title and abstract screened: n  = 992
Articles excluded: n  = 740
Exclusion criteria:
1: Main focus on other condition than hepatic cystic lesions: n  = 581
2: No focus on diagnostic features: n  = 132
3: Not involving humans: n  = 27
Retrieved for full text evaluation: n  = 252
Figure 1  Selection process of retrieved articles.
Figure 2  Simple cyst. A: On abdominal ultrasonography. Ultrasonography (USG) demonstrating a large simple cyst occupying the right hepatic lobe. Note the sharp 
and smooth border, oval shape, and anechoic echo pattern with the absence of septations and strong posterior wall echoes. The cyst size is indicated by the dotted 
lines; B: On abdominal computed tomography. Computed tomography demonstrating a sharply defined homogeneous hypodense cystic lesion (arrow) occupying the 
right hepatic lobe, which was diagnosed as a simple cyst. 
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immuno diagnostic tests[47]. USG shows a round or oval-
shaped, anechoic or atypical (i.e., snowflake-like inclusions 
or floating laminated membranes) echo pattern with mul-
tiple septa confined by a laminated border (Table 2)[47]. 
USG has a reported specificity of  90% and is used in 
combination with CT when surgical treatment is consid-
ered. MRI has not been proven to be cost-effective and 
has no added value[48]. The currently used serodiagnostic 
tests to reveal E. granulosus antibodies have a sensitivity of  
93.5% and specificity of  89.7%[49].
Therapy: The treatment of  CE, including surgery (open 
or laparoscopic), percutaneous treatments [e.g., puncture 
aspiration injection re-aspiration (PAIR) method] and 
chemotherapy[50], is indicated to reduce symptoms and 
prevent complications[51]. PAIR is the treatment of  choice 
for CE, as a recent review showed that PAIR resulted 
in parasitological clearance (i.e., negative serodiagnostic 
tests) in 95.8% of  cases[52]. 
Alveolar echinococcosis
Pathogenesis: AE is endemic in the Northern hemi-
sphere (e.g., North America, Asia, China, Japan and 
Europe). AE occurs when E. multilocularis eggs, found in 
the excrement of  foxes, are ingested. The spread from 
endemic areas to previously non-endemic Western Eu-
ropean countries is most likely due to an increasing fox 
population and spillover from these wild carnivores to 
domestic hosts[7,8]. 
Clinical features: The ingested eggs develop into an 
alveolar structure composed of  numerous small vesicles 
that vary in diameter from smaller than 1 mm to 3 cm. 
Each vesicle has the same wall structure as CE. These 
vesicles grow slowly and are able to reach a maximum di-
ameter of  15-20 cm, similar to simple cysts[53]. In approx-
imately 99% of  cases, the infection is initially confined to 
a solitary alveolar lesion in the liver[45]. After the primary 
infection, AE usually has an asymptomatic phase of  5-15 
years prior to the development of  symptoms. Symptoms 
are related to mass effect or are nonspecific, such as 
weight loss or fatigue[54]. In contrast to the encapsulated 
growth pattern of  CE, AE eventually leads to liver failure 
found in the temperate zones, including the Mediterra-
nean, Central Asia, Australia and some parts of  Ameri-
ca[44].
Because cyst growth in the liver is slow (ranging from 
1-5 millimetres in diameter per year), CE can remain 
asymptomatic for a long time. In approximately 90% of  
cases, the primary presentation is a spherical, fluid-filled 
vesicle with an inner cellular layer and an outer laminated 
layer located in the liver, lungs or both[45]. Symptoms oc-
cur when cysts exert mass effects within the organ or sur-
rounding tissues or rupture, often presenting as a sudden 
onset of  abdominal pain. Secondary cholangitis (rupture 
into the biliary tree), biliary obstruction and intraperito-
neal rupture followed by anaphylaxis are common com-
plications of  CE and require hospitalisation[6]. Worldwide 
mortality rate estimates vary between 2.2%-5.0%[45,46], 
although the exact mortality rate of  CE in developed 
countries remains unknown. 
Diagnostic features: The diagnosis of  CE is based 
on the following criteria: endemic region history, clini-
cal findings (e.g., abdominal pain, fever, chest pain, and 
dyspnea), pathognomonic USG features and positive 
Table 2  Ultrasonography features for the diagnosis of monocytic diseases of the liver
Simple cyst Cystic echinococcosis Alveolar echinococcosis Cystadenoma and cystadenocarcinoma
Border Sharp and smooth Laminated Irregular Irregular
Shape Spherical or oval Round or oval Irregular Round or oval
Echo pattern Anechoic1 Anechoic or atypical2 Hyperechogenic outer ring and 
hypoechogenic centre
Hypoechogenic with hyperechogenic 
septations
Appearance No septa Multiseptated Multivesicular Septated and/or solid structures 
(papillary projections)
Wall Strong posterior wall echoes Wall enhancement
Posterior acoustic 
feature
Relative3 accentuation of 
echoes
Dorsal shadowing 
(calcified areas)
Dorsal shadowing (calcified areas)
1Fluid-filled cavity; 2Snowflake-like inclusions or floating laminated membranes; 3Compared to echoes at a similar depth transmitted through normal 
adjacent hepatic tissue.
Figure 3  Complicated simple cyst on abdominal ultrasonography. Ultra-
sonography (USG) demonstrating a cystic lesion with a hyperechogenic echo 
pattern combined with internal echoes that mimic septations or solid portions 
(arrow) in a patient presenting with severe abdominal pain with a known history 
of multiple simple cysts (asterisks). Because of the known history of simple 
cysts, the lesion was diagnosed as a complicated simple cyst (i.e., intracystic 
haemorrhage). 
*
*
*
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due to an infiltrative neoplastic growth with potential me-
tastasis to adjacent and distant (e.g., lungs, spleen, bone, 
and brain) organs[55,56].
Diagnostic features: Typical USG aspects are observed 
in 70% of  cases and include irregular shape and border, 
hyperechogenic outer ring and hypoechogenic centre, 
multivesicular appearance and dorsal shadowing due to 
calcified areas (Table 2)[47]. Atypical USG aspects include 
small hyperechogenic nodules (amorphous AE), large 
lesions with massive necrosis (pseudocyst) and small 
calcified lesions (inert AE)[57]. In contrast to CE, MRI is 
superior to CT in detecting AE lesion margins[58,59]. Simi-
lar to CE, high diagnostic sensitivity (90%-100%) and 
specificity (95%-100%) are attained with serodiagnostic 
tests, and in 80%-95% of  cases, AE can be differentiated 
from CE with the help of  serologically obtained purified 
Echinococcus antigens[60]. 
Therapy: The approach to the management of  AE re-
sembles that of  a hepatic malignancy. The cornerstone 
of  treatment for AE includes radical surgery followed 
by a 2-year period of  chemotherapy[6]. A recent study 
concluded that AE can be cured in 42% of  cases by 
complete surgical removal of  the parasitic mass. Early 
diagnosis could even improve this rate further[61]. 
CYSTADENOMA AND 
CYSTADENOCARCINOMA
Pathogenesis
Cystadenoma and cystadenocarcinoma are biliary cyst 
tumours that originate from the biliary epithelium[62]. 
Analogous to simple cysts, cystadenoma is considered 
to be a congenital disorder[63]. The exact mechanism 
of  carcinogenesis in cystadenoma remains unknown. 
Several studies have suggested that cystadenocarcinoma 
develops from the ectopic remnants of  primitive foregut 
sequestered within the liver[63]. In contrast, the malignant 
transformation of  cystadenoma into cystadenocarcinoma 
is considered to be an alternative mechanism of  carcino-
genesis, as some cystadenocarcinomas may co-exist with 
cystadenoma[64]. This hypothesis is supported by the ob-
servation that the presence of  cystadenoma increases the 
chance of  developing cystadenocarcinoma[65].
Clinical features
Less than 5% of  all cystic lesions of  the liver are cystic 
neoplasms[2]. The clinical presentation of  cystadenoma 
and cystadenocarcinoma is asymptomatic or tends to 
mimic symptoms of  simple cysts or echinococcosis[66,67]. 
Studies have reported a predominance in women, with a 
mean age of  onset varying from 40-60 years[64,65]. Cyst-
adenomas appear to be slow growing, but exact growth 
rates are unknown. One case series evaluated 75 patients 
and recorded a variability in cyst size from 1.5-35 cm[68]. 
One study involving 63 cases diagnosed with cystadeno-
carcinoma demonstrated infiltrative growth in neighbour-
ing organs in 33 cases (52%) and distant metastases in 15 
cases (24%)[5]. For that reason, it is necessary to diagnose 
cystadenocarcinoma in an early stage. 
Laboratory findings
In general, liver function tests are normal. A review of  
13 cases found that serum concentrations of  γGT and al-
kaline phosphatase (AP) were elevated in 3 cases[69]. One 
study reported a rise in serum levels of  CEA in 3 of  22 
cystadenocarcinoma cases (14%) and a rise in the serum 
concentration of  CA 19-9 in 4 of  11 cases (36%)[5]. Simi-
lar results have been reported in cases with cystadenoma: 
one study showed elevated serum concentrations of  CEA 
or CA 19-9 in 2 of  3 cases[63]. Consequently, laboratory 
studies are not helpful in differentiating cystadenoma and 
cystadenocarcinoma from complicated cysts or echino-
coccosis.  
Diagnostic features
The USG characteristics of  cystic neoplasms for both 
cystadenoma and cystadenocarcinoma are the following: 
a round or oval shape, irregular border, hypoechogenic 
echo pattern with hyperechogenic septations or solid 
structures (i.e., papillary projections), wall enhancement 
and dorsal shadowing due to calcified areas (Table 2)[2]. 
Because of  these typical cystic neoplasmic features, which 
are absent in simple cysts, USG is a useful technique to 
easily discriminate between cystic neoplasms and simple 
cysts[2]. Like USG, CT and MRI show markedly similar 
characteristics for cystadenoma and cystadenocarcinoma: 
internal septations, thickened and irregular wall, papillary 
projections, calcifications and wall enhancements[62]. Cyst-
adenomas predominantly have thinner septa and more 
regular walls[70], whereas solid structures, intracystic haem-
orrhage and vascularised septations on contrast-enhanced 
CT are more suspicious for cystadenocarcinoma[62]. How-
ever, in most cases, differentiation between cystadenoma 
and cystadenocarcinoma is not possible[1]. The same 
problem arises in differentiating echinococcosis and com-
plicated cysts from cystadenoma and cystadenocarcinoma 
because in many cases, intracystic haemorrhage, calcifica-
tions and septations are present in these lesions[2,62]. 
Recent advances in technology have made diffusion-
weighted magnetic resonance imaging (DWI) a promising 
MRI technique for liver lesion detection and characteri-
sation[71]. DWI depicts the rate of  diffusion of  water 
molecules between tissues, given as the apparent diffu-
sion coefficient (ADC)[72]. Generally, high ADC values 
are measured in cystic and necrotic tissue, which allow a 
relatively free diffusion of  water, whereas low ADC val-
ues are an indication of  cell-rich tissue (e.g., tumour tis-
sue)[22,73,74]. However, because of  an overlap of  ADC val-
ues, differentiating cystic neoplasms, echinococcosis and 
complicated cysts is not possible with DWI[75]. Therefore, 
additional immunodiagnostic tests are needed to rule 
out echinococcosis. Fine needle aspiration (FNA) could 
be of  additional help to exclude complicated cysts[76]; 
however, due to the risk of  malignancy, FNA is generally 
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not performed. In contrast, CEUS can be helpful in dif-
ferentiating cystadenoma and cystadenocarcinoma from 
complicated cysts when USG, CT or MRI is inconclusive. 
CEUS characterises the vascular flow within septa in 
cystadenoma and cystadenocarcinoma, which is absent 
in complicated cysts[29-31]. Nonetheless, surgical resection 
remains the golden standard for diagnosing cystadenoma 
and cystadenocarcinoma when CEUS is not available.
Therapy
The primary treatment of  cystadenoma and cystadeno-
carcinoma is hepatic resection. A study in which 66 cases 
of  cystadenocarcinoma were subjected to hepatic resec-
tion described a 3-year survival rate of  74%[5].
PCLD AND ADPKD
Polycystic liver disease
Polycystic liver disease (PLD) is arbitrarily defined as 
the presence of  > 20 liver cysts[77]. Autosomal dominant 
polycystic liver disease (PCLD) and autosomal dominant 
polycystic kidney disease (ADPKD) are two distinct ge-
netic disorders associated with the development of  poly-
cystic livers[78]. Liver function, as judged by parameters 
of  liver synthesis, is not affected in PLD, as functional 
hepatic tissue remains unaffected[77,79]. 
Pathogenesis
During embryogenesis, the intrahepatic bile ducts are 
formed from a cylindrical layer of  cells (i.e., ductal plate) 
surrounding each portal vein. Incorrect involution of  
the ductal plate results in ductal plate malformation 
(DPM)[80,81]. DPM consists of  excess embryonic bile duct 
structures in a ductal plate configuration that does not 
communicate with the normally developed intrahepatic 
bile ducts. The progressive dilatation of  these excess in-
trahepatic structures during life results in multiple liver 
cysts[82]. Similar to simple cysts, these cysts contain a clear, 
bile-like fluid and an inner lining of  cholangiocytes[83]. 
Genetics
PCLD was historically considered a phenotypic vari-
ant of  ADPKD[84]. However, the presence of  PLD in 
the absence of  renal cysts led to the belief  that PCLD 
should be regarded as a separate entity[85]. The discovery 
of  a familial form of  PLD[86], genetically distinct from 
the heterozygous mutation in genes PKD1 and PKD2 
identified in ADPKD[87], ultimately led to the identifi-
cation of  heterozygous mutations in genes encoding 
SEC63 and PRKCSH[88-90]. Mutation analysis identified a 
heterozygous mutation in PRKCSH (15%) and SEC63 
(5%) in approximately 20% of  studied PCLD cases[91]. In 
contrast, a PKD1 mutation was found in 85% of  cases of  
ADPKD, and a PKD2 mutation was found in the remain-
ing cases[92]. 
PRKCSH and SEC63 encode hepatocystin and 
SEC63 proteins, respectively. Hepatocystin acts in the 
folding process of  proteins, while SEC63 acts as part of  
the endoplasmic reticulum translocon[93]. Unfortunately, 
the exact mechanism of  cystogenesis in PCLD remains 
unclear. Polycystin 1 and 2, encoded by PKD1 and PKD2, 
respectively, are important for adequate functioning of  
the primary cilium[94]. Its therefore suggested that primary 
cilia play a central pathogenic role in the mechanism of  
hepatic cystogenesis in ADPKD[78].
Clinical features
The extra polarisation of  137 identified PCLD cases in 
a specific adherence region (the Netherlands) led to an 
estimated PCLD prevalence of  1 per 158000[77]. This 
number is most likely an underestimation of  the true 
prevalence because only symptomatic patients referred to 
tertiary centres were included in this study, and PCLD of-
ten remains asymptomatic[95]. ADPKD is the most com-
mon monogenetic disorder, with a world-wide estimated 
prevalence of  0.10%-0.25%[96], and it is responsible for 
approximately 8%-10% of  cases with end-stage renal dis-
ease[97]. Although ADPKD is primarily characterised by 
the presence of  renal cysts[98], liver cysts are considered 
the most prevalent extra-renal manifestation of  ADP-
KD[99,100]. Indeed, one study involving 230 ADPKD cases 
found an overall prevalence of  83%[101]. However, the 
exact prevalence of  PLD in ADPKD is still unknown. 
PCLD is predominantly confined to the liver, but a few 
renal cysts can also be present, which leads to difficul-
ties in the accurate differentiation between PCLD and 
ADPKD[79,99]. Although renal cysts in ADPKD ultimately 
lead to renal failure, renal function remains unaffected in 
the presence of  PCLD-associated renal cysts[102].
PLD is predominantly discovered during the 
fourth or fifth decade of  life and is more severe in fe-
males[77,96,103,104]. PCLD tends to lead to a higher number 
and greater volume of  liver cysts[79]. The number of  
pregnancies, increased age and severity of  renal disease 
are considered additional risk factors for liver cyst growth 
in ADPKD[105]. PLD is mainly asymptomatic, but me-
chanical complaints can arise in a subset of  patients[79,106]. 
Complications such as intracystic haemorrhage and infec-
tion are rare and typically occur in large cysts[106]. 
Laboratory findings
PLD causes increased γGT and AP levels in both PCLD 
and ADPKD patients[77]. Occasionally, increased serum 
aspartate aminotransferase (AST) is also found in ADP-
KD[79,107]. Renal function remains intact in PCLD, where-
as ADPKD patients show a rise in serum creatinine due 
to impaired renal function[102]. 
Diagnostic features
PLD is detected with the use of  USG, CT or MRI. 
USG, which is accurate, non-invasive and low cost, is the 
preferred imaging modality for both PCLD and ADP-
KD[108,109]. Currently, there are no generally accepted USG 
criteria for PCLD. One study suggested that the diagno-
sis can be made in case of  a positive family history of  
PCLD and the presence of  > 4 liver cysts[78]. However, 
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diagnosing ADPKD is usually relatively straightforward 
when enlarged bilateral cystic kidneys are present in com-
bination with a positive family history for ADPKD[102]. In 
case of  a negative family history, screening direct family 
members with USG can be helpful to reveal asymptom-
atic ADPKD. Because mutation analysis for ADPKD has 
no clinical implications, its use is limited to family mem-
bers of  ADPKD patients involved in kidney donation 
programs. In 2009, the Pei USG criteria were developed 
because the original Ravine USG criteria for diagnosing 
ADPKD appeared to be insufficient[110,111]. Table 3 gives 
an overview of  the USG criteria for diagnosing ADPKD 
when the causative gene is unknown. For example, in 
case of  a positive ADPKD family history, diagnosis can 
be made when ≥ 3 renal cysts are unilaterally present in 
individuals aged 15 to 39 years[110]. ADPKD should be 
considered when there are > 10 bilateral renal cysts pres-
ent in the absence of  other renal or extra-renal disease 
that can cause renal cysts[108]. When PCLD or ADPKD 
criteria are not met, multiple simple cysts are most likely 
responsible for the hepatic cystic lesions. 
ADPKD is characterised by an increased risk of  de-
veloping vascular manifestations. Hypertension occurs 
in approximately 50%-70% of  patients, and almost half  
of  these hypertensive patients are reported to have left 
ventricular hypertrophy (LVH)[112]. Mitral valve prolapse 
is observed in 25% of  patients and intracranial aneu-
rysms in 4%-12% of  patients[112]. As a result, magnetic 
resonance angiography (MRA) must be performed when 
ADPKD patients have a positive family history of  in-
tracranial aneurysms because the rupture of  aneurysms 
is reported to be responsible for 4%-7% of  deaths in 
affected ADPKD families[113]. In contrast to ADPKD, 
several studies have shown that PCLD patients do not 
appear to have an increased risk of  vascular malforma-
tions. One study involving 19 PCLD cases reported 
hypertension in 10.5% of  cases, mitral valve prolapse 
in 0% and aneurysms in 5.3%[79]. Another study involv-
ing 38 PCLD cases found mitral valve prolapse in 1 case 
(2.6%)[114]. Subsequently, targeted screening is not advised 
for PCLD.
Therapy
The main objective of  therapy is to reduce liver cyst 
volume to diminish mass effect-related symptoms[115]. 
Hence, the only indication for reducing cyst volume is 
when a PLD patient reports symptoms that can be linked 
to the polycystic liver[116]. 
Surgical procedures, such as aspiration-sclerotherapy 
and fenestration, are indicated when PLD consists of  
large cysts confined to a limited part of  the liver. In more 
extensive disease, segmental hepatic resection or even 
liver transplantation is imperative to relieve symptoms[117]. 
Future medical therapies include somatostatin analogues, 
as several clinical trials with lanreotide and octreotide 
achieved polycystic liver volume reduction in PCLD and 
ADPKD[118-123]. 
CONCLUSION
Cystic lesions of  the liver encompass a wide spectrum of  
disorders. As a result of  the frequent use of  abdominal 
imaging techniques in recent years, the incidence of  so-
called coincidental cysts has increased. Simple cysts are 
the most prevalent and have a tendency to follow a be-
nign course. However, complicated cysts, echinococcosis 
and cystic neoplasms (e.g., cystadenoma and cystadeno-
carcinoma), which cause a diagnostic enigma, demand 
accurate diagnosis in the early stage because specific 
treatment could be required. Furthermore, the presence 
of  multiple hepatic cystic lesions must raise the suspicion 
of  PCLD or ADPKD and requires further screening. 
USG remains the most accurate, non-invasive and 
cost-effective imaging modality for diagnosing simple 
cysts. Despite recent advances (e.g., contrast-enhanced CT 
and DWI), distinguishing complicated cysts from echino-
coccosis and cystic neoplasms remains impossible with 
USG, CT or MRI alone. Because of  an ever-increasing 
spread of  Echinococcus to previously non-endemic regions 
and its initial quiescent phase after primary infection, it is 
necessary to exclude echinococcosis. Serodiagnostic tests 
have high sensitivity and specificity to reveal Echinococcus 
antibodies. Subsequently, CEUS can be used to accurately 
and reliably exclude cystic neoplasms by demonstrating 
the absence of  any enhancement within the hepatic cystic 
lesion. Therefore, when CEUS is available, it reduces the 
need for surgical resection. 
The detection of  multiple liver cysts requires USG 
screening of  both kidneys and extensive family history 
taking regarding the occurrence of  ADPKD or PCLD. 
When PCLD or ADPKD criteria are not met, multiple 
simple cysts are most likely responsible for the hepatic 
cystic lesions. PCLD or ADPKD could eventually be di-
agnosed through USG follow-up. 
To summarise, we developed a diagnostic algorithm 
by integrating recent advances with conventional diagnos-
tic tools (Figure 4). Our diagnostic algorithm facilitates 
evidence-based clinical decision making when clinicians 
are confronted with coincidental hepatic cystic lesions 
on USG. Further development of  USG- and MRI-based 
techniques, such as CEUS and DWI, will probably lead 
to further improvement of  hepatic cystic lesion charac-
terisation. 
Table 3  Ultrasonography criteria for the diagnosis of 
autosomal dominant polycystic kidney disease
Family history positive1
Unknown genotype
Age (yr)
   ≥ 15 and ≤ 39 ≥ 3 unilateral renal cysts
   ≥ 40 and ≤ 59 ≥ 2 bilateral renal cysts
   ≥ 60 ≥ 4 bilateral renal cysts
Family history negative
> 10 bilateral renal cysts, with the exclusion of renal or extra-renal 
disease causing renal cysts
1Exclude autosomal dominant polycystic kidney disease when < 2 unilat-
eral renal cysts and ≥ 40 years of age.
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